Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15563839 | 0.94 | RPS6KA2 (0.42) | PARP1KIF11KDM1APARP10PARP11 | |
| SCHEMBL15563523 | 0.90 | PARP1 (0.53) | PARP1PARP10PARP11 | |
| SCHEMBL17046643 | 0.89 | PARP1 (0.45) | PARP1KIF11RPS6KA2 | |
| SCHEMBL15563176 | 0.89 | PARP1 (0.50) | PARP1RPS6KA2 | |
| SCHEMBL15563830 | 0.88 | PARP1 (0.58) | PARP1RPS6KA2 | |
| SCHEMBL15563328 | 0.88 | RPS6KA2 (0.38) | PARP1KIF11KDM1ARPS6KA2 | |
| SCHEMBL15564191 | 0.87 | PARP1 (0.48) | PARP1RPS6KA2 | |
| SCHEMBL17046582 | 0.87 | PARP1 (0.54) | PARP1PARP10PARP11RPS6KA2 | |
| SCHEMBL17046598 | 0.87 | PARP1 (0.45) | PARP1KDM1A | |
| SCHEMBL17046617 | 0.87 | PARP1 (0.59) | PARP1RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880036-B1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN LA ROCHE (CH) | 2017-03-08 | — | — | EP | claimed |
| US-9284321-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | HOFFMANN-LA ROCHE INC. (US) | 2016-03-15 | — | — | US | claimed |
| US-20150246922-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | claimed |
| EP-2880036-B1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN LA ROCHE (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-9284321-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | HOFFMANN-LA ROCHE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284321-B2 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | HOFFMANN-LA ROCHE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150246922-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246922-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246922-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246922-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | HTR1D, HTR1A, DRD2 | PARP1 57/4885KIF11 1813/4885KDM1A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.